COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study in Healthy Volunteers Comparing Two Different Liquid Formulations of Solifenacin With Each Other and With the Tablet Formulation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01406158
Recruitment Status : Completed
First Posted : August 1, 2011
Last Update Posted : August 24, 2011
Information provided by (Responsible Party):
Astellas Pharma Inc

Brief Summary:
A study in healthy volunteers comparing two different liquid formulations of solifenacin with each other and with the tablet formulation.

Condition or disease Intervention/treatment Phase
Pharmacokinetics of Solifenacin Succinate Healthy Volunteers Drug: Solifenacin Succinate Formulation A Drug: Solifenacin Succinate Formulation B Drug: Solifenacin Succinate Phase 1

Detailed Description:

Subjects will be randomized to one of six treatment sequences. The treatments will be separated by a minimum of 13 days between dosing.

Study drug will be administered after an overnight fast, and food will be restricted for an additional four hours after dosing. Except for the water provided with dosing, water will be restricted only during the hour before and the hour after dosing.

Subjects will stay at the study site for the first three days of each treatment period. Subjects will return to the study center each morning at the same time of the day for Days 4 through 11 of each study period for the pharmacokinetic blood draw and vital signs. Subjects will be in the study for at least 40 days.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: A Phase 1, Open-Label, Randomized, Single Dose, 3-Way Crossover Study to Assess the Relative Bioavailability of Solifenacin Liquid Suspension 10 mg (Formulation B) Versus Solifenacin Liquid Suspension 10 mg (Formulation A) and to Assess the Relative Bioavailability of Solifenacin Liquid Suspension 10 mg (Formulation A and B) Versus the VESIcare (Solifenacin Succinate) 10 mg Tablet in Healthy Volunteers
Study Start Date : May 2011
Actual Primary Completion Date : July 2011
Actual Study Completion Date : July 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Treatment A Drug: Solifenacin Succinate Formulation A
oral suspension
Other Name: YM905

Experimental: Treatment B Drug: Solifenacin Succinate Formulation B
oral suspension
Other Name: YM905

Experimental: Treatment T Drug: Solifenacin Succinate
oral tablet
Other Names:
  • VESIcare
  • YM905

Primary Outcome Measures :
  1. Pharmacokinetic assessment of AUC and maximum concentration (Cmax) through the analysis of blood samples [ Time Frame: Up to Day 11 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subject weighs at least 45 kg, and has a body mass index of 18 to 32 kg/m2
  • Subject has a normal 12-lead electrocardiogram (ECG)
  • Subject, if female, must be at least 2 years postmenopausal, surgically sterile, or practicing effective birth control, and is not pregnant or lactating
  • Subject has good venous access

Exclusion Criteria:

  • The subject has a history of any clinically significant disease or malignancy with the exception of non-melanoma skin cancer
  • The subject has a history of or currently has evidence of urinary retention, gastric retention, or uncontrolled narrow-angle-glaucoma
  • The subject has a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmia or torsade de pointes, structural heart disease, or family history of Long QT syndrome (suggested by sudden death of a close relative at a young age due to possible or probable cardiac causes)
  • The subject has a known hypersensitivity to VESIcare® or any of the excipients in the formulations, or the subject has a history of severe allergic or anaphylactic reactions
  • The subject has a history of consuming more than 15 units of alcoholic beverages per week, or has a history of alcoholism or substance abuse within the past two years prior to screening (Note: one unit = 12 ounces of beer, 4 ounces of wine, or 1 ounce of spirits)
  • The subject has used tobacco containing products or nicotine containing products within past six months
  • The subject has a supine mean systolic blood pressure < 90 or > 160 mmHg and a mean diastolic blood pressure < 50 or > 90 mmHg, or pulse rate < 40 or >100 beats per minute
  • The subject is known to be positive for human immunodeficiency virus antibody
  • The subject has a positive test for hepatitis C antibody or hepatitis B antigen
  • The subject's laboratory test results are outside the normal limits and considered to be clinically significant
  • The subject has had treatment with prescription or non-prescription drugs, including complementary and alternative medicines or over-the-counter medications, with the exception of hormonal contraceptives, hormone replacement therapy, and occasional use of acetaminophen within 14 days prior to inclusion into the study
  • The subject anticipates an inability to abstain from alcohol or caffeine use throughout the duration of the study or from grapefruit, Seville oranges, star fruit, or any products containing these items from throughout the duration of the study
  • The subject has received an experimental agent within past 30 days or ten half-lives, whichever is longer
  • The subject has had any significant blood loss
  • The subject has any clinically significant history of gastrointestinal symptoms such as nausea, abdominal discomfort or upset, or heartburn in the four weeks prior to clinic admission, or a history of any gastrointestinal surgery except for appendectomy or cholecystectomy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01406158

Layout table for location information
United States, Wisconsin
Spaulding Clinical Research
West Bend, Wisconsin, United States, 53095
Sponsors and Collaborators
Astellas Pharma Inc
Layout table for investigator information
Study Director: Medical Director Astellas Pharma Global Development
Layout table for additonal information
Responsible Party: Astellas Pharma Inc Identifier: NCT01406158    
Other Study ID Numbers: 905-CL-080
First Posted: August 1, 2011    Key Record Dates
Last Update Posted: August 24, 2011
Last Verified: August 2011
Keywords provided by Astellas Pharma Inc:
Solifenacin succinate
Healthy Volunteers
Additional relevant MeSH terms:
Layout table for MeSH terms
Solifenacin Succinate
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Urological Agents